Stem Cell Infusion Therapy For COPD

copd 1024pxChronic Obstructive Pulmonary Disease is a degenerative condition of the lungs. Overtime, long term injury to the parnechyma results in restricted airways and hyperinflation of the lungs. The thickening of airways increases airway resistance resulting in air trapping .These progressive changes decrease quality of life, leading to disability and eath. Emphysema is profoundly caused by smoking and unfortunately, long after the smoke exposure ceases, the inflammatory process persists.

Symptoms and Treatment of COPD

The symptoms of COPD include shortness of breath, reduced exercise tolerance, fatigue and chronic wet cough. These symptoms are managed by the use of steroids to suppress the immune system. Antibiotics are given for recurring infections such as pneumonia. The downside of these treatments is that the patient is at increased risk for infections and cancer due to long term suppression of the immune system. These medications simply control the symptoms but further weaken the patient as a whole. Unfortunately, with this medical model COPD is terminal and will cause disability and death.

Stem Cell Infusion for COPD

Mesenchymal stem cells (MSC’s) are showing promising results for COPD patients, even in advanced patients. The mesenchymal stem cells modulate the immune system by inhibiting the overactive chemicals such as IL-6 and enhancing the regulatory T cells. The MSC’s stimulate the body’s own regenerative and repair capabilities in the areas of injured tissue. The stem cells  travel to the lungs via paracrine signaling and begin secreting growth factors and cytokines to begin repair. For more information on how stem cells work see our FAQ page.

Umbilical cord derived stem cells (UCB-MSC’s) have the advantage of bone marrow derived stem cells (BM-MSC’s) and adipose derived stem cells due to their smaller size. This prevents possible pulmonary entrapment that has occured with some infusions of BM-MSC’s and adipose stem cells. In addition adipose derived stem cells pose increased risks for infection. Most COPD patients are older and generally unhealthy. The bone marrow and adipose derived stem cells from the patient reflect the poor health of the host. UCB-MSC’s are just 9 months old and have been shown to be more robust than the host’s less viable stem cells and respond strongly to paracrine signaling compared to the host stem cells.

What Results can I expect?

The treatment for COPD is simple and results may be seen quickly.  Results vary depending on the progression of the disease, age, and overall health. As with any regenerative treatment, the earlier in the course of disease process, the better the outcome. Many clinical trials are under way and we have seen patients regain quality of life and reduce or eliminate the need for oxygen therapy For more information on how this treatment can help you call 480-535-7868 or click here to request a complimentary consult with the physician.

The use of treatments on this site require doctor evaluation and laboratory testing along with consideration of the risks, benefits, and other options before they are recommneded or prescribed. No offer is being made for any treatment without undergoing a medical records review or clinical work up, discussion of the nature of the evidence, risks, and benefits for a therapeutic approach specific to the patient including a discussion of treatment options. Therapies may be designed to strengthen the lungs, rather than as specific treatments for a certain medical condition.

􏰥􏰆􏰇 􏰌􏰔􏰇 􏰈􏰩 􏰄􏰎􏰇􏰂􏰄􏰟􏰇􏰉􏰄􏰔 􏰞􏰒􏰔􏰃􏰌􏰔􏰔􏰇􏰞 􏰈􏰉 􏰄􏰆􏰒􏰔 􏰔􏰒􏰄􏰇 􏰎􏰇􏰶􏰌􏰒􏰎􏰇 􏰞􏰈􏰃􏰄􏰈􏰎 􏰇􏰪􏰂􏰍􏰌􏰂􏰄􏰒􏰈􏰉􏰢 􏰍􏰂􏰯􏰈􏰎􏰂􏰄􏰈􏰎􏰏 􏰄􏰇􏰔􏰄􏰒􏰉􏰋 􏰂􏰉􏰞 􏰃􏰈􏰉􏰔􏰒􏰞􏰇􏰎􏰂􏰄􏰒􏰈􏰉 􏰈􏰩 􏰄􏰆􏰇 􏰎􏰒􏰔􏰮􏰔􏰢 􏰯􏰇􏰉􏰇􏰩􏰒􏰄􏰔􏰢 􏰂􏰉􏰞 􏰈􏰄􏰆􏰇􏰎 􏰈􏰨􏰄􏰒􏰈􏰉􏰔 􏰯􏰇􏰩􏰈􏰎􏰇 􏰄􏰆􏰇􏰏 􏰂􏰎􏰇 􏰎􏰇􏰃􏰈􏰟􏰟􏰇􏰉􏰞􏰇􏰞 􏰈􏰎 􏰨􏰎􏰇􏰔􏰃􏰎􏰒􏰯􏰇􏰞􏰭 􏰦􏰈 􏰈􏰩􏰩􏰇􏰎 􏰒􏰔 􏰯􏰇􏰒􏰉􏰋 􏰟􏰂􏰞􏰇 􏰩􏰈􏰎 􏰂􏰉􏰏 􏰄􏰎􏰇􏰂􏰄􏰟􏰇􏰉􏰄 􏰧􏰒􏰄􏰆􏰈􏰌􏰄 􏰌􏰉􏰞􏰇􏰎􏰋􏰈􏰒􏰉􏰋 􏰂 􏰨􏰎􏰈􏰨􏰇􏰎 􏰃􏰍􏰒􏰉􏰒􏰃􏰂􏰍 􏰧􏰈􏰎􏰮􏰚􏰌􏰨􏰢 􏰞􏰒􏰔􏰃􏰌􏰔􏰔􏰒􏰈􏰉 􏰂􏰯􏰈􏰌􏰄 􏰄􏰆􏰇 􏰉􏰂􏰄􏰌􏰎􏰇 􏰈􏰩 􏰄􏰆􏰇 􏰇􏰪􏰒􏰞􏰇􏰉􏰃􏰇􏰢 􏰎􏰒􏰔􏰮􏰔􏰢 􏰂􏰉􏰞 􏰯􏰇􏰉􏰇􏰩􏰒􏰄􏰔 􏰩􏰈􏰎 􏰂 􏰄􏰆􏰇􏰎􏰂􏰨􏰇􏰌􏰄􏰒􏰃 􏰂􏰨􏰨􏰎􏰈􏰂􏰃􏰆 􏰔􏰨􏰇􏰃􏰒􏰩􏰒􏰃 􏰄􏰈 􏰄􏰆􏰇 􏰨􏰂􏰄􏰒􏰇􏰉􏰄 􏰒􏰉􏰃􏰍􏰌􏰞􏰒􏰉􏰋 􏰂 􏰞􏰒􏰔􏰃􏰌􏰔􏰔􏰒􏰈􏰉 􏰈􏰩 􏰄􏰎􏰇􏰂􏰄􏰟􏰇􏰉􏰄 􏰈􏰨􏰄􏰒􏰈􏰉􏰔􏰭 􏰥􏰆􏰇􏰎􏰂􏰨􏰒􏰇􏰔 􏰟􏰂􏰏 􏰯􏰇 􏰞􏰇􏰔􏰒􏰋􏰉􏰇􏰞 􏰄􏰈 􏰔􏰄􏰎􏰇􏰉􏰋􏰄􏰆􏰇􏰉 􏰏􏰈􏰌􏰎 􏰒􏰟􏰟􏰌􏰉􏰇 􏰔􏰏􏰔􏰄􏰇􏰟 􏰄􏰈 􏰎􏰇􏰞􏰌􏰃􏰇 􏰄􏰆􏰇 􏰎􏰒􏰔􏰮􏰢 􏰞􏰌􏰎􏰂􏰄􏰒􏰈􏰉􏰢 􏰂􏰉􏰞 􏰒􏰉􏰄􏰇􏰉􏰔􏰒􏰄􏰏 􏰈􏰩 􏰒􏰉􏰩􏰇􏰃􏰄􏰒􏰈􏰌􏰔 􏰂􏰉􏰞 􏰒􏰉􏰩􏰍􏰂􏰟􏰟􏰂􏰄􏰈􏰎􏰏 􏰞􏰒􏰔􏰇􏰂􏰔􏰇 􏰎􏰂􏰄􏰆􏰇􏰎 􏰄􏰆􏰂􏰉 􏰂􏰔 􏰔􏰨􏰇􏰃􏰒􏰩􏰒􏰃 􏰄􏰎􏰇􏰂􏰄􏰟􏰇􏰉􏰄􏰔 􏰩􏰈􏰎 􏰄􏰆􏰇 􏰃􏰈􏰎􏰈􏰉􏰂􏰪􏰒􏰎􏰌􏰔 􏰄􏰆􏰂􏰄 􏰃􏰂􏰌􏰔􏰇􏰔

􏰥􏰆􏰇 􏰌􏰔􏰇 􏰈􏰩 􏰄􏰎􏰇􏰂􏰄􏰟􏰇􏰉􏰄􏰔 􏰞􏰒􏰔􏰃􏰌􏰔􏰔􏰇􏰞 􏰈􏰉 􏰄􏰆􏰒􏰔 􏰔􏰒􏰄􏰇 􏰎􏰇􏰶􏰌􏰒􏰎􏰇 􏰞􏰈􏰃􏰄􏰈􏰎 􏰇􏰪􏰂􏰍􏰌􏰂􏰄􏰒􏰈􏰉􏰢 􏰍􏰂􏰯􏰈􏰎􏰂􏰄􏰈􏰎􏰏 􏰄􏰇􏰔􏰄􏰒􏰉􏰋 􏰂􏰉􏰞 􏰃􏰈􏰉􏰔􏰒􏰞􏰇􏰎􏰂􏰄􏰒􏰈􏰉 􏰈􏰩 􏰄􏰆􏰇 􏰎􏰒􏰔􏰮􏰔􏰢 􏰯􏰇􏰉􏰇􏰩􏰒􏰄􏰔􏰢 􏰂􏰉􏰞 􏰈􏰄􏰆􏰇􏰎 􏰈􏰨􏰄􏰒􏰈􏰉􏰔 􏰯􏰇􏰩􏰈􏰎􏰇 􏰄􏰆􏰇􏰏 􏰂􏰎􏰇 􏰎􏰇􏰃􏰈􏰟􏰟􏰇􏰉􏰞􏰇􏰞 􏰈􏰎 􏰨􏰎􏰇􏰔􏰃􏰎􏰒􏰯􏰇􏰞􏰭 􏰦􏰈 􏰈􏰩􏰩􏰇􏰎 􏰒􏰔 􏰯􏰇􏰒􏰉􏰋 􏰟􏰂􏰞􏰇 􏰩􏰈􏰎 􏰂􏰉􏰏 􏰄􏰎􏰇􏰂􏰄􏰟􏰇􏰉􏰄 􏰧􏰒􏰄􏰆􏰈􏰌􏰄 􏰌􏰉􏰞􏰇􏰎􏰋􏰈􏰒􏰉􏰋 􏰂 􏰨􏰎􏰈􏰨􏰇􏰎 􏰃􏰍􏰒􏰉􏰒􏰃􏰂􏰍 􏰧􏰈􏰎􏰮􏰚􏰌􏰨􏰢 􏰞􏰒􏰔􏰃􏰌􏰔􏰔􏰒􏰈􏰉 􏰂􏰯􏰈􏰌􏰄 􏰄􏰆􏰇 􏰉􏰂􏰄􏰌􏰎􏰇 􏰈􏰩 􏰄􏰆􏰇 􏰇􏰪􏰒􏰞􏰇􏰉􏰃􏰇􏰢 􏰎􏰒􏰔􏰮􏰔􏰢 􏰂􏰉􏰞 􏰯􏰇􏰉􏰇􏰩􏰒􏰄􏰔 􏰩􏰈􏰎 􏰂 􏰄􏰆􏰇􏰎􏰂􏰨􏰇􏰌􏰄􏰒􏰃 􏰂􏰨􏰨􏰎􏰈􏰂􏰃􏰆 􏰔􏰨􏰇􏰃􏰒􏰩􏰒􏰃 􏰄􏰈 􏰄􏰆􏰇 􏰨􏰂􏰄􏰒􏰇􏰉􏰄 􏰒􏰉􏰃􏰍􏰌􏰞􏰒􏰉􏰋 􏰂 􏰞􏰒􏰔􏰃􏰌􏰔􏰔􏰒􏰈􏰉 􏰈􏰩 􏰄􏰎􏰇􏰂􏰄􏰟􏰇􏰉􏰄 􏰈􏰨􏰄􏰒􏰈􏰉􏰔􏰭 􏰥􏰆􏰇􏰎􏰂􏰨􏰒􏰇􏰔 􏰟􏰂􏰏 􏰯􏰇 􏰞􏰇􏰔􏰒􏰋􏰉􏰇􏰞 􏰄􏰈 􏰔􏰄􏰎􏰇􏰉􏰋􏰄􏰆􏰇􏰉 􏰏􏰈􏰌􏰎 􏰒􏰟􏰟􏰌􏰉􏰇 􏰔􏰏􏰔􏰄􏰇􏰟 􏰄􏰈 􏰎􏰇􏰞􏰌􏰃􏰇 􏰄􏰆􏰇 􏰎􏰒􏰔􏰮􏰢 􏰞􏰌􏰎􏰂􏰄􏰒􏰈􏰉􏰢 􏰂􏰉􏰞 􏰒􏰉􏰄􏰇􏰉􏰔􏰒􏰄􏰏 􏰈􏰩 􏰒􏰉􏰩􏰇􏰃􏰄􏰒􏰈􏰌􏰔 􏰂􏰉􏰞 􏰒􏰉􏰩􏰍􏰂􏰟􏰟􏰂􏰄􏰈􏰎􏰏 􏰞􏰒􏰔􏰇􏰂􏰔􏰇 􏰎􏰂􏰄􏰆􏰇􏰎 􏰄􏰆􏰂􏰉 􏰂􏰔 􏰔􏰨􏰇􏰃􏰒􏰩􏰒􏰃 􏰄􏰎􏰇􏰂􏰄􏰟􏰇􏰉􏰄􏰔 􏰩􏰈􏰎 􏰄􏰆􏰇 􏰃􏰈􏰎􏰈􏰉􏰂􏰪􏰒􏰎􏰌􏰔 􏰄􏰆􏰂􏰄 􏰃􏰂􏰌􏰔􏰇􏰔 􏰖􏰗􏰘􏰙􏰕􏰚􏰛􏰜􏰭
􏰥􏰆􏰇 􏰌􏰔􏰇 􏰈􏰩 􏰄􏰎􏰇􏰂􏰄􏰟􏰇􏰉􏰄 􏰞􏰒􏰔􏰃􏰌􏰔􏰔􏰇􏰞 􏰈􏰉 􏰄􏰆􏰒􏰔 􏰔􏰒􏰄􏰇 􏰎􏰇􏰶􏰌􏰒􏰎􏰇 􏰞􏰈􏰃􏰄􏰈􏰎 􏰇􏰪􏰂􏰍􏰌􏰂􏰄􏰒􏰈􏰉􏰢 􏰍􏰂􏰯􏰈􏰎􏰂􏰄􏰈􏰎􏰏 􏰄􏰇􏰔􏰄􏰒􏰉􏰋 􏰂􏰉􏰞 􏰃􏰈􏰉􏰔􏰒􏰞􏰇􏰎􏰂􏰄􏰒􏰈􏰉 􏰈􏰩 􏰄􏰆􏰇 􏰎􏰒􏰔􏰮􏰔􏰢 􏰯􏰇􏰉􏰇􏰩􏰒􏰄􏰔􏰢 􏰂􏰉􏰞 􏰈􏰄􏰆􏰇􏰎 􏰈􏰨􏰄􏰒􏰈􏰉􏰔 􏰯􏰇􏰩􏰈􏰎􏰇 􏰄􏰆􏰇􏰏 􏰂􏰎􏰇 􏰎􏰇􏰃􏰈􏰟􏰟􏰇􏰉􏰞􏰇􏰞 􏰈􏰎 􏰨􏰎􏰇􏰔􏰃􏰎􏰒􏰯􏰇􏰞􏰭 􏰦􏰈 􏰈􏰩􏰩􏰇􏰎 􏰒􏰔 􏰯􏰇􏰒􏰉􏰋 􏰟􏰂􏰞􏰇 􏰩􏰈􏰎 􏰂􏰉􏰏 􏰄􏰎􏰇􏰂􏰄􏰟􏰇􏰉􏰄 􏰧􏰒􏰄􏰆􏰈􏰌􏰄 􏰌􏰉􏰞􏰇􏰎􏰋􏰈􏰒􏰉􏰋 􏰂 􏰨􏰎􏰈􏰨􏰇􏰎 􏰃􏰍􏰒􏰉􏰒􏰃􏰂􏰍 􏰧􏰈􏰎􏰮􏰚􏰌􏰨􏰢 􏰞􏰒􏰔􏰃􏰌􏰔􏰔􏰒􏰈􏰉 􏰂􏰯􏰈􏰌􏰄 􏰄􏰆􏰇 􏰉􏰂􏰄􏰌􏰎􏰇 􏰈􏰩 􏰄􏰆􏰇 􏰇􏰪􏰒􏰞􏰇􏰉􏰃􏰇􏰢 􏰎􏰒􏰔􏰮􏰔􏰢 􏰂􏰉􏰞 􏰯􏰇􏰉􏰇􏰩􏰒􏰄􏰔 􏰩􏰈􏰎 􏰂 􏰄􏰆􏰇􏰎􏰂􏰨􏰇􏰌􏰄􏰒􏰃 􏰂􏰨􏰨􏰎􏰈􏰂􏰃􏰆 􏰔􏰨􏰇􏰃􏰒􏰩􏰒􏰃 􏰄􏰈 􏰄􏰆􏰇 􏰨􏰂􏰄􏰒􏰇􏰉􏰄 􏰒􏰉􏰃􏰍􏰌􏰞􏰒􏰉􏰋 􏰂 􏰞􏰒􏰔􏰃􏰌􏰔􏰔􏰒􏰈􏰉 􏰈􏰩 􏰄􏰎􏰇􏰂􏰄􏰟􏰇􏰉􏰄 􏰈􏰨􏰄􏰒􏰈􏰉􏰔􏰭 􏰥􏰆􏰇􏰎􏰂􏰨􏰒􏰇􏰔 􏰟􏰂􏰏 􏰯􏰇 􏰞􏰇􏰔􏰒􏰋􏰉􏰇􏰞 􏰄􏰈 􏰔􏰄􏰎􏰇􏰉􏰋􏰄􏰆􏰇􏰉 􏰏􏰈􏰌􏰎 􏰒􏰟􏰟􏰌􏰉􏰇 􏰔􏰏􏰔􏰄􏰇􏰟 􏰄􏰈 􏰎􏰇􏰞􏰌􏰃􏰇 􏰄􏰆􏰇 􏰎􏰒􏰔􏰮􏰢 􏰞􏰌􏰎􏰂􏰄􏰒􏰈􏰉􏰢 􏰂􏰉􏰞 􏰒􏰉􏰄􏰇􏰉􏰔􏰒􏰄􏰏 􏰈􏰩 􏰒􏰉􏰩􏰇􏰃􏰄􏰒􏰈􏰌􏰔 􏰂􏰉􏰞 􏰒􏰉􏰩􏰍􏰂􏰟􏰟􏰂􏰄􏰈􏰎􏰏 􏰞􏰒􏰔􏰇􏰂􏰔􏰇 􏰎􏰂􏰄􏰆􏰇􏰎 􏰄􏰆􏰂􏰉 􏰂􏰔 􏰔􏰨􏰇􏰃􏰒􏰩􏰒􏰃 􏰄􏰎􏰇􏰂􏰄􏰟􏰇􏰉􏰄􏰔 􏰩􏰈􏰎 􏰄􏰆􏰇 􏰃􏰈􏰎􏰈􏰉􏰂􏰪􏰒􏰎􏰌􏰔 􏰄􏰆􏰂􏰄 􏰃􏰂􏰌􏰔􏰇􏰔 􏰖􏰗􏰘􏰙􏰕􏰚􏰛􏰜􏰭

Close Menu